We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Insulin Sensitivity of the Brain in Pathogenesis of Diabetes Mellitus Type 2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00638209
Recruitment Status : Unknown
Verified March 2008 by University Hospital Tuebingen.
Recruitment status was:  Recruiting
First Posted : March 19, 2008
Last Update Posted : March 19, 2008
Sponsor:
Collaborator:
German Research Foundation
Information provided by:
University Hospital Tuebingen

Brief Summary:
The purpose of the study is to investigate whether insulin sensitivity of the human brain correlates with insulin sensitivity of the liver.

Condition or disease Intervention/treatment
Human Physiology of Energy Homeostasis Drug: Human insulin Drug: Saline

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Insulin Sensitivity of the Brain in Pathogenesis of Diabetes Mellitus Typ 2
Study Start Date : February 2008
Estimated Primary Completion Date : May 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: I Drug: Human insulin
Placebo Comparator: P Drug: Saline



Primary Outcome Measures :
  1. Insulin effect on cortical function (spectral analysis) [ Time Frame: 2 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18-70 Risk factor(s) for type 2 diabetes (e.g. overweight, family history of diabetes)

Exclusion Criteria:

  • Type 2 diabetes pregnancy acute or chronic diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00638209


Contacts
Contact: Andreas Fritsche, MD +49 7071 29 80590 andreas.fritsche@med.uni-tuebingen.de

Locations
Germany
University Hospital Tuebingen, Internal Medicine IV Recruiting
Tuebingen, Germany, 72076
University Hospital Tuebingen Recruiting
Tuebingen, Germany, 72076
Contact: Andreas Fritsche    +49 7071 29 80590    andreas.fritsche@med.uni-tuebingen.de   
Sponsors and Collaborators
University Hospital Tuebingen
German Research Foundation

Responsible Party: Prof. Andreas Fritsche, University Hospital Tuebingen, Internal Medicine IV
ClinicalTrials.gov Identifier: NCT00638209     History of Changes
Other Study ID Numbers: MEG-KFO-2
EudraCT 2006-004734-32
KFO-114
First Posted: March 19, 2008    Key Record Dates
Last Update Posted: March 19, 2008
Last Verified: March 2008

Additional relevant MeSH terms:
Diabetes Mellitus
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hyperinsulinism
Insulin, Globin Zinc
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs